Champions Oncology (CSBR) Liabilities and Shareholders Equity (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Liabilities and Shareholders Equity of $27.0 million for Q2 2026, down 16.56% year-over-year from $32.3 million in Q2 2025, and down 5.13% quarter-over-quarter from $28.4 million in Q1 2026.
Champions Oncology (CSBR) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
Champions Oncology's Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $27.0 million for Q2 2026.
- In Q2 2026, Liabilities and Shareholders Equity fell 16.56% year-over-year to $27.0 million; the TTM figure through Apr 2026 stood at $116.1 million (up 2.65% YoY), while the FY2026 annual figure was $27.0 million, down 16.56% from the prior year.
- Liabilities and Shareholders Equity for Q2 2026 stood at $27.0 million, down from $28.4 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $36.4 million in Q4 2022, with the low at $24.9 million in Q3 2024.
- The 5-year median for Liabilities and Shareholders Equity is $30.4 million (2025), against an average of $30.6 million.
- The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity jumped 32.95% in 2022, then decreased 25.9% in 2024.
- Champions Oncology's Liabilities and Shareholders Equity stood at $36.4 million in 2022, then slipped by 22.19% to $28.3 million in 2023, then retreated by 10.79% to $25.2 million in 2024, then grew by 19.5% to $30.2 million in 2025, then fell by 10.52% to $27.0 million in 2026.
- Business Quant data shows CSBR's Liabilities and Shareholders Equity at $27.0 million in Q2 2026, $28.4 million in Q1 2026, and $30.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn | 26.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 26.99 Mn |
| Jan 31, 2026 | 28.45 Mn |
| Oct 31, 2025 | 30.16 Mn |
| Jul 31, 2025 | 30.55 Mn |
| Apr 30, 2025 | 32.34 Mn |
| Jan 31, 2025 | 30.63 Mn |
| Oct 31, 2024 | 25.24 Mn |
| Jul 31, 2024 | 24.93 Mn |
| Apr 30, 2024 | 26.13 Mn |
| Jan 31, 2024 | 26.79 Mn |
| Oct 31, 2023 | 28.29 Mn |
| Jul 31, 2023 | 29.91 Mn |
| Apr 30, 2023 | 34.31 Mn |
| Jan 31, 2023 | 36.15 Mn |
| Oct 31, 2022 | 36.36 Mn |
| Jul 31, 2022 | 34.39 Mn |
| Apr 30, 2022 | 35.38 Mn |
| Jan 31, 2022 | 33.58 Mn |
| Oct 31, 2021 | 29.30 Mn |
| Jul 31, 2021 | 28.11 Mn |